Brief recoveries followed by sudden gap-downs—a trap designed to lure buyers before the next leg down.
Indian equity markets are enduring their sharpest monthly decline since the pandemic, as foreign institutional investors withdraw at a historic pace — a reflection of dollar strength, geopolitical unease, and a broader loss of conviction that no brief rally has yet managed to reverse. The market finds itself in a familiar human predicament: the appearance of recovery masking a deeper fragility, where hope is repeatedly offered and just as repeatedly withdrawn. Analysts counsel not optimism or despair, but discipline — the ancient wisdom of knowing when to wait rather than act.
- Foreign investors have sold over Rs 1.22 lakh crore this month across 20 consecutive sessions, a relentless exodus that has left the market structurally weakened and sentiment deeply scarred.
- The Nifty has fallen more than 9% month-to-date — its steepest drop since the 2020 pandemic crash — with every brief recovery quickly absorbed by renewed selling pressure, trapping traders who mistake tactical bounces for genuine reversals.
- The rupee has hit an all-time intraday low of 94.96, down 4% since late February, compounding the pressure on foreign appetite and signaling that macro headwinds are far from resolved.
- Technical analyst Sudeep Shah is urging a 'sell on rise' posture, identifying 22,600 and 22,400 as the next critical support levels, while the 23,150–23,200 range is expected to cap any meaningful recovery attempt.
- Pockets of resilience are emerging — Lupin, Anthem Biosciences, Emcure Pharma, HEG, and Graphite India all show technical breakouts — but broader recovery hinges on dollar moderation and an easing of geopolitical tensions that remain unresolved.
Indian equity markets are caught in a punishing rhythm: brief recoveries draw in hopeful traders, only for renewed selling to arrive within days and erase the gains. This cycle has repeated since late February, when geopolitical tensions first ignited a broad sell-off, and technical analysts see little evidence it is close to breaking.
Sudeep Shah of SBI Securities frames the current environment as one demanding discipline above all else. His core recommendation — sell on any rise — reflects a view that short-term pullbacks are corrective bounces, not the beginning of a genuine trend reversal. The conditions for a durable recovery, he argues, require a meaningful weakening of the US dollar and a reduction in geopolitical risk. Neither appears imminent.
The scale of foreign institutional selling has been extraordinary. Investors offloaded Rs 4,367 crore in a single session and have now sold for 20 consecutive days, bringing the month's total outflow to Rs 1,22,379 crore. Even during market recoveries, the selling has continued — a signal that institutions are using bounces as exit opportunities. The rupee's fall to an all-time intraday low of 94.96 underscores the dollar strength that is suppressing foreign appetite for Indian assets.
Nifty has shed more than 9% month-to-date, its worst monthly performance since the pandemic crash of 2020. The index remains below its key moving averages, momentum indicators point downward, and the long-short ratio in futures has stayed in the 10–15% range — reflecting the dominance of short positions and the absence of meaningful short covering. Shah places the nearest support at 22,600, with further downside targets at 22,400 and 22,200, and significant resistance at 23,150–23,200 on any recovery attempt.
Global gas supply disruptions are adding another layer of pressure, pushing up input costs for energy-dependent industries and clouding earnings outlooks. The risk of further earnings downgrades is real, and in this environment even minor negative developments can trigger outsized sell-offs.
Midcap and smallcap indices have held up somewhat better than the broader market, though Shah cautions that this relative strength may be temporary. The next two to three weeks will be telling.
For traders willing to act selectively, Shah identifies specific opportunities with defined risk parameters. Lupin has held a key support zone multiple times and is showing relative outperformance against the Nifty. Anthem Biosciences has broken out of a consolidation range with strong volume and improving momentum indicators. Emcure Pharma has cleared a significant resistance level that had held three times since listing. HEG and Graphite India have both moved into positive technical territory within their Bollinger Bands. The broader lesson the market is offering, however, remains unchanged: in conditions like these, patience and discipline matter far more than conviction.
The Indian stock market is caught in a grinding cycle of false hope and sudden collapse. Brief recoveries spanning just a few trading days give way to sharp gap-down openings, pulling in traders who believe the worst has passed, only to be punished when selling pressure returns within days. This pattern has repeated itself since late February, when geopolitical tensions first sparked a broad market sell-off, and it shows no sign of breaking.
Sudeep Shah, head of technical and derivatives research at SBI Securities, sees the current environment as one demanding strict discipline and careful risk management. His recommendation is straightforward: sell on any rise. Short-term pullbacks, he argues, are likely to remain corrective in nature—tactical bounces, not the start of a genuine trend reversal. Unless the US dollar weakens meaningfully and geopolitical risks ease, foreign institutional investors will continue to flee Indian equities, keeping the market volatile and vulnerable to further downside.
The numbers tell a stark story. Foreign investors offloaded Rs 4,367 crore on a single Friday and have now extended their selling streak to 20 consecutive sessions. The cumulative outflow for the month stands at Rs 1,22,379 crore—a staggering sum that reflects a complete loss of conviction among institutional money. Even during brief market recoveries, the selling has persisted, signaling that these bounces are being used as exit opportunities, not entry points. The Indian rupee has weakened to an all-time intraday low of 94.96, down 4 percent since late February, a reflection of dollar strength that typically dampens foreign investor appetite.
On the technical front, the Nifty index has shed more than 9 percent month-to-date, marking its steepest monthly decline since the pandemic crash of 2020. The index remains pinned below its key moving averages, and momentum indicators point decisively downward. Shah identifies the 22,650–22,600 band as the nearest support zone. If the index breaks convincingly below 22,600, the next downside targets arrive at 22,400 and then 22,200. To the upside, the 23,150–23,200 range is expected to pose significant resistance to any recovery attempt. The long-short ratio in index futures has remained muted in the 10–15 percent range since early March, highlighting the dominance of short positions and the minimal evidence of short covering that might signal a shift in sentiment.
Compounding the market's weakness are disruptions to global gas supply, which are pushing up input costs for energy-dependent industries, squeezing margins, and delaying investment decisions. Earnings outlooks are clouding, and the risk of further earnings downgrades looms. This backdrop of macro headwinds and persistent foreign selling has created a fragile sentiment where even minor negative developments can trigger outsized sell-offs.
Yet not all segments have deteriorated equally. The Nifty Midcap 100 and Smallcap 100 indices have held up relatively better than the broader market, though Shah cautions that this outperformance can be deceptive. Market leadership typically rotates only once broader confidence returns, and the coming two to three weeks will be crucial for monitoring whether small-cap strength is genuine or merely a temporary refuge.
For traders willing to take positions, Shah has identified specific opportunities. Lupin has rebounded steadily from the Rs 2,240–2,260 support zone, which has held multiple times since early March. The stock trades above its key moving averages, and a fresh breakout in the Lupin-to-Nifty ratio chart signals strong relative outperformance. Shah recommends accumulating the stock in the Rs 2,340–2,320 zone with a stop-loss at Rs 2,265, targeting Rs 2,500 in the short term. Anthem Biosciences has broken out of a consolidation range between Rs 649–625 with healthy volume support. The RSI has rebounded sharply from 40 to near 60, and the MACD crossover above the signal line reinforces positive momentum. Shah suggests accumulating in the Rs 683–678 zone with a stop-loss at Rs 660, targeting Rs 730.
Emcure Pharma has delivered a decisive head-and-shoulders neckline breakout, with the Rs 1,580–1,590 zone—which had acted as stiff resistance three times since listing—now convincingly breached on healthy volume. The RSI is trending higher and has broken out of a downward-sloping trendline. As long as the stock sustains above Rs 1,580, the uptrend is likely to extend further. HEG and Graphite India have both moved above the midline of their Bollinger Bands, indicating a shift toward positive bias and potential for further upside, provided their support zones hold. The broader message remains unchanged: in this market, patience and discipline matter more than conviction.
Citas Notables
Unless there is a clear moderation in dollar strength along with an improvement in the geopolitical situation, FII flows are likely to remain under pressure, keeping equity markets volatile and susceptible to downside risks in the near term.— Sudeep Shah, SBI Securities
Any short-term pullbacks are likely to remain corrective in nature rather than mark the beginning of a sustainable trend reversal.— Sudeep Shah, on his 'sell on rise' strategy
La Conversación del Hearth Otra perspectiva de la historia
Why does Shah keep saying 'sell on rise' when there are clearly stocks breaking out to the upside?
Because the breakouts in individual stocks are happening within a market that's fundamentally broken. The Nifty is down 9 percent this month, foreign money is fleeing, and the dollar is strong. A stock can look good on its own charts while the tide is going out.
So he's saying don't trust the bounces?
Exactly. The pattern since late February is: brief recovery, then gap-down opening, then selling resumes. It's happened repeatedly. Traders see a bounce and think the worst is over, but it's a trap. The selling pressure always comes back.
What would actually change his mind?
Dollar weakness and geopolitical improvement. Those are the two things keeping foreign investors out. Until the US dollar moderates and tensions ease, the outflows will continue. That's the macro anchor.
But if someone wanted to buy, which stocks does he actually like?
Lupin and Anthem Biosciences. Both have broken out of consolidation zones with strong volume and momentum indicators turning positive. But the caveat is clear: these are trades within a deteriorating market. You're betting on relative strength, not absolute strength.
What's the risk if someone ignores his warning and goes long?
The Nifty could break below 22,600 and test 22,400 or 22,200. And if that happens, even the stocks that look good on their own charts will get dragged down. Individual stock strength doesn't protect you from a market-wide selloff.
How long does he think this lasts?
He's watching the next two to three weeks closely. The small-cap outperformance might signal something shifting, but it could also be a false signal. Until foreign money stops leaving and the macro picture improves, the volatility and downside risk remain.